IL2 CD25 fusion protein (Bristol-Myers Squibb)

N/A

Report date: 2024/06/27 12:01:28

Base Information

Drug NameIL2 CD25 fusion protein (Bristol-Myers Squibb)

Drug Alias NameIL2/CD25 (Bristol-Myers Squibb)IL2 CD25 (Bristol-Myers Squibb)Interleukin-2/interleukin-2 receptor alpha fusion protein (Bristol-Myers Squibb)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionInterleukin-2 modulatorsInterleukin-2 receptor alpha chain modulatorsRegulatory T-lymphocytes stimulants

TargetsInterleukin-2Interleukin-2 receptor alpha chain

Therapy Area/IndicationsAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Miami

China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb Company

Inactive CompaniesN/A

Active IndicationsAutoimmune Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A